GILD catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04251416A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaYale University · Endometrial CarcinomaActive, not recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06048133Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Nataliya Uboha · Biliary Tract CarcinomaActive, not recruitingRCUSCollaboratorGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06104592Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLH. Lee Moffitt Cancer Center and Research Institute · Large B-cell LymphomaRecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05838521A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerYale University · Cervical CancerRecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06682728Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceUniversity of California, Irvine · Urothelial CarcinomaRecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT07197164Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant PatientsFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · COVID - 19RecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05675579A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage...M.D. Anderson Cancer Center · Breast CancerActive, not recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT06528483Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · Bladder CancerNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT06029972Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisGilead Sciences · Ulcerative Colitis | GILDLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple...Laura Huppert, MD, BA · Stage III Breast Cancer | PFECollaboratorGILDCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · DIFFUSE LARGE B-CELL LYMPHOMA | GILDCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT06029972Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisGilead Sciences · Ulcerative ColitisActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 2NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple...Laura Huppert, MD, BA · Stage III Breast CancerActive, not recruitingPFECollaboratorGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · DIFFUSE LARGE B-CELL LYMPHOMARecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04724018Sacituzumab Govitecan Plus EV in Metastatic UCDana-Farber Cancer Institute · Urothelial Cancer | GILDCollaborator | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 1/Phase 2NCT04724018Sacituzumab Govitecan Plus EV in Metastatic UCDana-Farber Cancer Institute · Urothelial CancerRecruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.